Steve A Kay

US Patent:

20050081268, Apr 14, 2005

Filed:

Apr 8, 2002

Appl. No.:

10/473945

Inventors:

Steve Kay - San Diego CA, US
Tina Kuhlmann - San Diego CA, US
Richard Lerner - La Jolla CA, US

International Classification:

A01H001/00
C12N015/82
C12N005/04

US Classification:

800288000, 435419000

Abstract:

A genetically modified plant cell containing a heterologous nucleotide sequence encoding a bioluminescent polypeptide, which is expressed in amount sufficient to produce at least about 750,000 photons of visible light/mm/second, is provided, as is a visibly bioluminescent transgenic plant, which contains such a genetically modified plant cell. Also provided is a recombinant nucleic acid molecule, which contains a plant translational enhancer operatively linked to a nucleotide sequence encoding a bioluminescent polypeptide. In addition, methods of producing a genetically modified plant cell that is visibly bioluminescent introducing a transgene encoding a bioluminescent polypeptide into a plant cell, whereby the bioluminescent polypeptide is expressed at a level that produces at least about 750,000 photons of visible light/mm/second are provided, as are kits containing such visibly bioluminescent compositions.

US Patent:

20050149993, Jul 7, 2005

Filed:

Aug 8, 2003

Appl. No.:

10/637710

Inventors:

Satchidananda Panda - San Diego CA, US
John Hogenesch - Encinitas CA, US
Ignacio Provincio - Arlington VA, US
Steve Kay - San Diego CA, US

Assignee:

IRM LLC - Hamilton
Uniformed Services University of the Health Sciences - Bethesda MD
The Scripps Research Institute - La Jolla CA

International Classification:

A01K067/027
C12N005/06

US Classification:

800003000, 800018000, 435354000

Abstract:

The present invention provides a transgenic non-human animals comprising a disruption in the melanopsin gene as well as methods for using the animals to identify agents useful for modulating circadian rhythm in animals.

US Patent:

20050186138, Aug 25, 2005

Filed:

Oct 13, 2004

Appl. No.:

10/965607

Inventors:

John Hogenesch - Encinitas CA, US
Trey Sato - La Jolla CA, US
Steve Kay - San Diego CA, US

Assignee:

IRM, LLC - Hamilton
The Scripps Research Institute - La Jolla CA

International Classification:

A61K049/00

US Classification:

424009200

Abstract:

The present invention provides methods of identifying circadian rhythm modulators and methods of modulating circadian rhythm in animals.

US Patent:

20090142793, Jun 4, 2009

Filed:

Sep 23, 2008

Appl. No.:

12/236374

Inventors:

Steve A. Kay - San Diego CA, US
John B. Hogenesch - Encinitas CA, US
M. Fernanda Ceriani - Buenos Aires, AR
Satchidananda Panda - San Diego CA, US

International Classification:

C12Q 1/02
G01N 33/68

US Classification:

435 29, 436 86

Abstract:

Screening assays for identifying agents that modulate BK channel activity and further modulate the sleep/wake cycle in a subject, circadian regulated locomotor activity in a subject, or both are provided, as are agents identified using such screening assays. Also provided are methods of modulating the sleep/wake cycle in a subject and methods of modulating circadian regulated locomotor activity in a subject by administering an agent that modulates BK channel activity to the subject, for example, an agent identified by a screening assay as disclosed.

US Patent:

20120184004, Jul 19, 2012

Filed:

Jul 22, 2010

Appl. No.:

13/383409

Inventors:

Steve A. Kay - San Diego CA, US
Ewa Lis - Lakeside CA, US
Susan Golden - Del Mar CA, US
Michael Melnick - San Francisco CA, US
Dawn M. Adin - Germantown MD, US
James W. Golden - Del Mar CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

C12P 7/64
C12N 1/13
C12N 1/00
C12N 15/63

US Classification:

435134, 4353201, 4352572, 4353171

Abstract:

Provided herein are methods and compositions for the production of renewable fatty acids from photosynthetic prokaryotic microorganisms, such as a blue green algae, any specie of the phylum Cyanophyta, a chloroplast of a green algae and/or a Cyanobacterium. Engineered or natural strains of these organisms or organelles can be used to produce both saturated and unsaturated fatty acids with variable chain length specificity from 8-18 carbons. The fatty acids can then be secreted into the culture medium, allowing for rapid, continuous and efficient separation of fatty acid product without harvesting of cell mass.

US Patent:

20120232003, Sep 13, 2012

Filed:

Mar 15, 2010

Appl. No.:

13/255641

Inventors:

Joseph S. Takahashi - Dallas TX, US
Steve A. Kay - San Diego CA, US

International Classification:

A61K 31/4045
A61K 31/4985
A61P 3/06
A61K 38/26
A61P 3/10
A61K 38/22
C07D 209/14

US Classification:

514 72, 514415, 514 69, 514249, 548507

Abstract:

The present invention relates to methods and compositions for the treatment or prevention of type 2 diabetes by administering an effective amount of a melatonin receptor agonist to a human subject in need of such treatment or prevention.

US Patent:

7427489, Sep 23, 2008

Filed:

Jun 17, 2003

Appl. No.:

10/464817

Inventors:

Steve A. Kay - San Diego CA, US
John B. Hogenesch - Encinitas CA, US
M. Fernanda Ceriani - Buenos Aires, AR
Satchidananda Panda - San Diego CA, US

Assignee:

The Scripps Research Institute - La Jolla CA
IRM LLC - Hamilton

International Classification:

G01N 33/53

US Classification:

435 721, 800 3

Abstract:

Screening assays for identifying agents that modulate BK channel activity and further modulate the sleep/wake cycle in a subject, circadian regulated locomotor activity in a subject, or both are provided, as are agents identified using such screening assays. Also provided are methods of modulating the sleep/wake cycle in a subject and methods of modulating circadian regulated locomotor activity in a subject by administering an agent that modulates BK channel activity to the subject, for example, an agent identified by a screening assay as disclosed.